BDBM267453 US10688100, Compound 36::US10966985, Compound 36::US9718822, 36::US9750744, Example 36::US9902741, Example 36

SMILES CC1(C)CNC(=O)c2cnn3ccc(nc23)N2CCC[C@@H]2c2cc(F)cnc2OC1

InChI Key InChIKey=LTTXNEAUXULKJC-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 267453   

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 55nMpH: 7.5Assay Description:The ability of a compound to bind to TrkA was measured by Invitrogen's LanthaScreen Eu Kinase Binding Assay. In this assay, His-tagged recombinan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2018
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound to bind to TrkA was measured by Invitrogen's LanthaScreen Eu Kinase Binding Assay. In this assay, His-tagged recombinan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
Go to US Patent

TargetHigh affinity nerve growth factor receptor(Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 55nMAssay Description:The ability of a compound to bind to TrkA was measured by Invitrogen's LanthaScreen Eu Kinase Binding Assay. In this assay, His-tagged recombinan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/21/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.700nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 6.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.200nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/22/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS(Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.700nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [G2032R](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 6.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [L2026M](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.5nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase ROS [D2033N](Human)
Array Biopharma

US Patent
LigandPNGBDBM267453(US9718822, 36 | US9750744, Example 36 | US9902741,...)
Affinity DataIC50: 0.200nMAssay Description:The potency of a compound inhibiting wild type and exemplary mutant ROS1 kinases was determined using CisBio's HTRF Kinease-TK assay technology. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/9/2021
Entry Details
Go to US Patent